YD Bio Ltd
About YD Bio Ltd
YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization. Its operations include DNA methylation-based oncology testing programs in the United States under an LDT framework with CLIA-certified and CAP-accredited laboratory partners. The Company also provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination and compliance-focused support for clinical development programs. It maintains ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia. The Company operates in the United States and Taiwan, with Taiwan generating maximum revenue.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $596.8K
- Net income
- -$8.3M
- Total assets
- $13.8M
- Market cap
- $213.2M
Source: SEC EDGAR · updated Jun 8, 2026
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $213.2M
- Shares outstanding
- 71.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 29, 2025
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $8.3M in FY2025.
- Trading 87% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review YD Bio Ltd.
Write a review
News about YD Bio Ltd
News & sentiment via Polygon.io
